The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma

Cancer

Volumn 98, Issue 4, 2003, Pages 730-736

  Mizutani, Yoichi ^a   Wada, Hiromi ^b   Yoshida, Osamu ^b   Fukushima, Masakazu ^c   Kawauchi, Akihiro ^a   Nakao, Masahiro ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 fluorouracil; Platelet derived endothelial cell growth factor; Renal cell carcinoma; Thymidine phosphorylase; Vascular endothelial growth factor

Indexed keywords

PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; THYMIDINE PHOSPHORYLASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; THIN LAYER CHROMATOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL RATE; THYMIDINE PHOSPHORYLASE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0042071584     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11570     Document Type: Article

References (30)

1. Folkman J. What is the evidence that tumours are angiogenesis dependent? N Engl J Med. 1990;285:82-86.
2. O'Brien TS, Harris AL. Angiogenesis in urological malignancy. Br J Urol. 1995;76:675-682.
3. Yoshino S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int J Urol. 1995;2:156-160.
4. Horak ER, Leek R, Klenk N, Le Jeune S, Smith K, Stuart N. Angiogenesis assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet. 1992;340:1120-1124.
5. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-10934.
6. Bicknell R, Harris AL. Novel growth regulatory factors and tumour angiogenesis. Eur J Cancer. 1991;27:781-785.
7. Nanus DM, Schmitz DB, Motzer RJ. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst. 1993;85:1597-1599.
8. Takahashi A, Sasaki H, Kim S. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placental growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994;54:4233-4237.
9. Brown L, Berse B, Jackman R, Tognazzi K, Manseau E, Dvorak H. Increased expression of vascular permeability factor (VEGF) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993;143:1255-1262.
10. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989;338:557-562.
11. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S. Angiogenic factor. Nature. 1992;356:668.
12. Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A. 1995;92:998-1002.
13. Haraguchi M, Kazutaka M, Uemura K, Sumizawa T, Furukawa T, Yamada K. Angiogenic activity of enzymes. Nature. 1994;368:198.
14. Zimmerman M, Seidenberg J. Deoxyribosyl transfer. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues. J Biol Chem. 1964;239:2618-2621.
15. Reynolds K, Farzaneh F, Collins WP, Campbell S, Bourne TH, Lawton F. Correlation of ovarian malignancy with expression of platelet-derived endothelial growth factor. J Natl Cancer Inst. 1994;86:1234-1238.
16. Umazono Y, Takebayashi Y, Nishiyama K, et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol. 1997;15:2570-2578.
17. Sobin LH, Wittekind C, editors. TNM classification of malignant tumors, 6th edition. New York: John Wiley & Sons, 2002.
18. Inaba M, Mitsuhashi J, Sawada H, et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res. 1996;87:212-220.
19. Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 1986;46:20-28.
20. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4:1013-1019.
21. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T, Ishitsuka H. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull. 1996;19:1407-1411.
22. Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by Adriamycin. Cancer Res. 2000;60:2912-2918.
23. Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer. 2001;92:287-293.
24. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6-receptor monoclonal antibody. Cancer Res. 1995;55:590-596.
25. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer. 2002;38:167-176.
26. Kinsui H, Ueda T, Suzuki H, et al. Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method. Jpn J Cancer Res. 2002;93:340-345.
27. Pinedo HM, Peters GJ. 5-fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988;6:1653-1664.
28. Santi DV, McHenry CS, Sommer H. Mechanisms of interaction of thymidylate synthase with 5-fluorodeoxyuridine. Biochemistry. 1974;13:471-480.
29. Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999;5:2289-2296.
30. Matsushita S, Nitanda T, Furukawa T, et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res. 1999;59:1911-1916.